SAN FRANCISCO, Calif. – November 7, 2022 – Today, Phil Inc., a patient access platform company that revolutionizes life science product commercialization, announced its technology solution now offers expanded functionality for companies developing prescription digital therapeutics (PDTs). Using Phil’s platform, digital health companies can simplify the healthcare journey for patients with their prescription, manage both pharmacy and medical benefits processes and improve access to prescriptions.
PDTs deliver medical interventions that physicians prescribe directly to patients using evidence-based, clinically evaluated software intended to treat and manage a broad spectrum of diseases and disorders. At times, insurance plans don’t cover PDTs as a pharmacy benefit, making access to these innovative therapies difficult through traditional pharmacies and hubs. Unlike traditional prescription access tools, the Phil platform manages both pharmacy and medical benefits processes. Over time, the software learns, helping companies evolve business rules and provides data insights about the process, to ultimately ensure that patients have access to the PDTs that they were prescribed.
“It is encouraging to work with a technology company like Phil to help deliver our treatment, Luminopia, to patients in need, as the company’s expertise in providing patients easy access to digital solutions helps to ensure an improved healthcare experience for patients and caregivers,” said Scott Xiao, Co-Founder and Chief Executive Officer of Luminopia, Inc. “As we see the industry evolve further with the development and coverage of PDTs, we are pleased to have even more opportunities to meet patients where they are at and leverage such an innovative platform to achieve our goals.”
Referring to Regulora, metaMe Health’s PDT treatment for IBS pain, Chief Executive Officer Tim Rudolphi said, “Phil has made the prescription fulfillment process simple for us, but more importantly simple for our prescribers and their patients. We’re developing innovative prescription digital therapeutics to combat many common chronic conditions, putting the power right in the hands of patients -- and Phil’s digital-first approach supports patients in the very same way.”
“Consumers expect a streamlined healthcare experience, much as they have grown accustomed to the experiences they have in travel and e-commerce. Especially as healthcare delivery methods have evolved due to the COVID-19 pandemic, more and more patients are seeking opportunities to connect virtually with providers, and we must also ensure that access to PDTs are convenient and affordable,” said Deepak Thomas, Founder and Chief Executive Officer at Phil, Inc. “We are pioneers in PDT commercialization, offering brands an innovative technology driven platform to prescribe, and helping to usher in new care delivery and prescription models.”
Learn more about Phil’s patient access platform.
About Phil, Inc.
Phil, Inc. revolutionizes life science product commercialization with technology to improve prescription access. Our patient access platform removes barriers to medication access and ensures patients can seamlessly start and adhere to therapy. Providing end-to-end visibility into the prescription life cycle, we unlock coverage and maximize reimbursement for brands while integrating into the lives and workflows of patients and providers. We combine a Silicon Valley mindset and deep pharma expertise with data insights and software-driven platform customization to create exponentially better patient outcomes, improve provider experience and elevate brand value.
Katie Beach Evoke Canale for Phil Katherine.Beach@canalecomm.com
Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance.